Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Total Debt (2016 - 2024)

Regen BioPharma (RGBPP) has disclosed Total Debt for 9 consecutive years, with $800149.0 as the latest value for Q2 2024.

  • On a quarterly basis, Total Debt rose 300.07% to $800149.0 in Q2 2024 year-over-year; TTM through Jun 2024 was $800149.0, a 300.07% increase, with the full-year FY2023 number at $349614.0, down 52.66% from a year prior.
  • Total Debt was $800149.0 for Q2 2024 at Regen BioPharma, up from $543685.0 in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $953981.0 in Q4 2023 to a low of $3048.0 in Q4 2021.
  • A 5-year average of $322553.6 and a median of $200000.0 in 2021 define the central range for Total Debt.
  • Peak YoY movement for Total Debt: tumbled 92.59% in 2021, then skyrocketed 7867.65% in 2022.
  • Regen BioPharma's Total Debt stood at $40000.0 in 2020, then tumbled by 92.38% to $3048.0 in 2021, then soared by 5956.92% to $184615.0 in 2022, then surged by 416.74% to $953981.0 in 2023, then fell by 16.13% to $800149.0 in 2024.
  • Per Business Quant, the three most recent readings for RGBPP's Total Debt are $800149.0 (Q2 2024), $543685.0 (Q1 2024), and $953981.0 (Q4 2023).